Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Aug 23, 2024
Emerging Company Profile
Borealis: Versant, Novartis launch Chinook’s RNA-targeting sequel
The research team behind Chinook are taking on renal diseases with cell type-specific delivery of oligonucleotide therapies.
BioCentury | Mar 15, 2024
Finance
Public equity report: PIPEs for Lexicon, Cybin, Regulus, Lexeo
Companies raise cash as they eye paths forward in diabetes, depression, kidney disease and Friedreich ataxia
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Jul 30, 2022
Data Byte
Assessing an expanse of ALS targets
Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Jun 26, 2019
Distillery Therapeutics
miR-17-92 gene therapy for ALS associated with SOD1 mutations
BioCentury | Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
BioCentury | Apr 20, 2017
Product R&D
Selectivity suite
How a Scripps team is finding RNA-binding small molecules
Items per page:
1 - 10 of 13